ABL Bio
ABL Bio is a company based in Seongnam-si, South Korea.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
ABL Bio is a company based in Seongnam-si, South Korea. Available evidence confirms only its identity as a company located in Seongnam-si, South Korea.
Recent events
ABL Bio and Sanofi announce Parkinson’s treatment collaboration[1]
Reported:
ABL Bio announced a collaboration and worldwide license agreement with Sanofi to develop and commercialize ABL301, a preclinical-stage treatment candidate for Parkinson’s disease and other potential indications. Sanofi is to receive worldwide exclusive development and commercialization rights once the transaction becomes effective.
GenScript and ABL Bio sign antibody-development partnership[2]
GenScript and South Korean biotechnology company ABL Bio signed an agreement to collaborate on the development of two bispecific-antibody projects. GenScript will license antibody assets and its platform to ABL Bio and provide preclinical pharmaceutical research and clinical-sample manufacturing services as the exclusive CDMO supplier for the projects.
GenScript and ABL Bio agree to develop bispecific antibodies[3]
Reported:
GenScript and South Korean biotechnology company ABL Bio signed an agreement for strategic collaboration on the development of two bispecific antibody programs. GenScript will license antibody and platform technologies to ABL Bio and provide exclusive preclinical pharmaceutical research and clinical-sample production services for the molecules.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/abl-bio-south-korea · Editorial policy · How profiles are compiled